MGMT and glioblastoma: An additional signature comprising a combination of four miRNAs (hsa‐let‐7a‐5p, hsa‐let‐7b‐5p, hsa‐miR‐615‐5p, and hsa‐miR‐125a‐5p) and the methylation status of MGMT has been shown to effectively stratify 102 glioblastoma patients into two distinct risk groups: low‐risk (54.9% of patients) and high‐risk (45.1% of patients) [116].